Location History:
- Regensburg, DE (2011)
- Princeton, NJ (US) (2013 - 2016)
Company Filing History:
Years Active: 2011-2016
Introduction
Hildegard Lobinger is a prominent inventor based in Princeton, NJ, recognized for her significant contributions to the field of pharmaceutical research. With a total of three patents to her name, her work primarily focuses on the development of crystal structures of SGLT2 inhibitors, which hold promise in treating conditions such as diabetes.
Latest Patents
Lobinger's latest patents detail the physical crystal structures of SGLT2 inhibitors and the processes for preparing these compounds. Specifically, her invention discusses a compound of the formula I, where key components are elucidated for their role in pharmaceutical compositions. The innovations not only cover the structural nuances of these compounds but also highlight methods for treating diseases like diabetes through the application of such structures.
Career Highlights
Throughout her career, Hildegard Lobinger has worked with renowned companies in the pharmaceutical industry, such as Bristol-Myers Squibb Company and AstraZeneca AB. Her expertise and innovative spirit have positioned her as a valuable contributor in the field of drug development.
Collaborations
Lobinger has collaborated with notable professionals, including her coworkers Jack Z. Gougoutas and Srividya Ramakrishnan. These collaborations have enabled advancements in understanding the structures and applications of SGLT2 inhibitors, furthering innovations in medicines aimed at combating diabetes.
Conclusion
Hildegard Lobinger's work exemplifies the essence of innovation in the pharmaceutical sphere. Through her groundbreaking patents and robust collaborations, she continues to influence the way we approach treatment for diabetes and related health conditions. Her contributions are an essential part of modern medical research and developments.